---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-000401"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T13:09:29.994358+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q4 2022 net income $117.3M ($4.33/diluted share), revenue surge to $160.3M on CSL deal

## Summary
- Q4 2022 revenue $160.3M vs $5.8M same quarter 2021; full-year revenue $206.0M vs $12.4M.
- Recorded net income $117.3M ($4.33/diluted) for Q4 vs net loss $38.7M ($1.47 loss) prior year.
- Received $200M upfront from CSL Seqirus in Dec 2022; $90M milestones invoiced in Mar 2023.
- Cash $391.9M at Dec 31, 2022; repaid $17.1M to Singapore, eliminating $33.3M non-recourse debt.
- ARCT-154 Phase 3 booster fully enrolled in Japan; ARCT-810 Phase 2 interim data expected later 2023.

## SEC filing metadata
- accession: 0001193805-23-000401
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000401/0001193805-23-000401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000401/e618402_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-000401
- JSON: https://secwatch.observer/filing/0001193805-23-000401.json
- Plain text: https://secwatch.observer/filing/0001193805-23-000401.txt

## Key facts
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported the year ended December 31, 2022 results: revenue $206.0 million, net income approximately $9.3 million, EPS $0.35 per diluted share.
  - Period: the year ended December 31, 2022
  - Revenue: $206.0 million
  - Net income: approximately $9.3 million
  - EPS: $0.35 per diluted share
  - Result: reported results
  source text: Total revenue for the year ended December 31, 2022, was $206.0 million compared with $12.4 million for the year ended December 31, 2021. The increase in fourth quarter and year-over-year revenues primarily relates to the $200 million upfront payment we received from the CSL transaction. Operating expenses : Total operating expenses for the three months ended December 31, 2022, were $38.8 million compared with $43.4 million for the three months ended December 31, 2021, and $50.2 million for the three months ended September 30, 2022. The decline in operating expenses when compared to the three months ended December 31, 2021, was primarily due to lower Covid-19 manufacturing and clinical related expenses. Total operating expenses for the year ended December 31, 2022, were $193.8 million compared with $215.2 million for the year ended December 31, 2021. Research and development expenses : Research and development expenses for the three months ended December 31, 2022, were $27.0 million com
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000401/0001193805-23-000401-index.htm
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported the three months ended December 31, 2022 results: revenue $160.3 million, net income approximately $117.3 million, EPS $4.33 per diluted share.
  - Period: the three months ended December 31, 2022
  - Revenue: $160.3 million
  - Net income: approximately $117.3 million
  - EPS: $4.33 per diluted share
  - Result: reported results
  source text: For the three months ended December 31, 2022, the Company reported revenue of $160.3 million compared with $5.8 million for the three months ended December 31, 2021, and $13.4 million for the three months ended September 30, 2022. Total revenue for the year ended December 31, 2022, was $206.0 million compared with $12.4 million for the year ended December 31, 2021. The increase in fourth quarter and year-over-year revenues primarily relates to the $200 million upfront payment we received from the CSL transaction. Operating expenses : Total operating expenses for the three months ended December 31, 2022, were $38.8 million compared with $43.4 million for the three months ended December 31, 2021, and $50.2 million for the three months ended September 30, 2022. The decline in operating expenses when compared to the three months ended December 31, 2021, was primarily due to lower Covid-19 manufacturing and clinical related expenses. Total operating expenses for the year ended December 31,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000401/0001193805-23-000401-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.